Kidswell Bio Corporation Logo

Kidswell Bio Corporation

Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.

4584 | T

Overview

Corporate Details

ISIN(s):
JP3386460004
LEI:
Country:
Japan
Address:
中央区新川一丁目2番12号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kidswell Bio Corporation is a biopharmaceutical company focused on the research and development of innovative pharmaceuticals and therapeutics, with a particular emphasis on pediatric diseases. Formerly known as Gene Techno Science and founded in 2001, the company's operations are centered around three core business segments: Biosimilars, leveraging its expertise in cell line development and CMC; New Biologics, which includes the development of novel antibodies for cancer and eye diseases; and Cell Therapy, which pioneers next-generation cellular medicines based on SHED (Stem cells from Human Exfoliated Deciduous teeth) to address unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 07:44
Registration Form
確認書
Japanese 8.1 KB
2025-11-14 07:43
Interim Report
半期報告書-第26期(2025/04/01-2026/03/31)
Japanese 189.9 KB
2025-06-30 08:33
Post-Annual General Meeting Information
臨時報告書
Japanese 24.0 KB
2025-06-27 08:36
Registration Form
確認書
Japanese 8.0 KB
2025-06-27 08:35
Governance Information
内部統制報告書-第25期(2024/04/01-2025/03/31)
Japanese 22.2 KB
2025-06-27 08:33
Annual Report
有価証券報告書-第25期(2024/04/01-2025/03/31)
Japanese 1.2 MB
2025-03-31 09:16
Regulatory News Service
臨時報告書
Japanese 18.2 KB
2024-12-26 07:56
Registration Form
有価証券届出書(組込方式)
Japanese 543.7 KB
2024-11-14 07:50
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-11-14 07:47
Interim Report
半期報告書-第25期(2024/04/01-2025/03/31)
Japanese 185.0 KB
2024-06-27 09:12
Post-Annual General Meeting Information
臨時報告書
Japanese 22.5 KB
2024-06-27 09:11
Governance Information
内部統制報告書-第24期(2023/04/01-2024/03/31)
Japanese 21.2 KB
2024-06-27 09:11
Registration Form
確認書
Japanese 8.1 KB
2024-06-27 09:10
Annual Report
有価証券報告書-第24期(2023/04/01-2024/03/31)
Japanese 1.1 MB
2024-06-07 08:39
Regulatory News Service
確認書
Japanese 8.1 KB

Automate Your Workflow. Get a real-time feed of all Kidswell Bio Corporation filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kidswell Bio Corporation

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kidswell Bio Corporation via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.